×
About 4 results

SGLT2, Fournier Gangrene Link Is 'Compelling'--What to Do?
https://emedicine.medscape.com/viewarticle/912369

Welcome to Impact Factor, your weekly commentary on a breaking medical study. I'm Perry Wilson. A new class of medications, the SGLT2 inhibitors, has been killing it lately, with study after study in the New England Journal of Medicine documenting their benefits in patients with diabetes. Many of us feel that these drugs will become a central part of diabetes therapy in the near future. The twi...

B Cell Test Predicts Alemtuzumab Autoimmunity in MS
https://www.medscape.com/viewarticle/937434

Sep 14th, 2020 - A common adverse effect of the multiple sclerosis (MS) treatment alemtuzumab (Lemtrada) may be predicted by pre-treatment levels of certain types of B cells, a new study suggests. Dr Paulette Walo "Alemtuzumab has proven to be an effective treatment for patients with highly active remitting relapsing MS, but adverse events may limit the use of this drug, particularly autoimmune adverse events, ...

Mefloquine-Associated Dizziness, Diplopia, and Central Serous Chorioretinopathy
https://www.medscape.com/viewarticle/871366_2

Background Mefloquine is a quinoline derivative antimalarial drug structurally related to quinine that has been previously widely used in the treatment and prophylaxis of malaria. Recently its popularity has declined as awareness has grown of the drug's focal central nervous system (CNS) toxicity, which is associated with a wide range of acute and chronic neurological sequelae including vertigo...

SGLT2, Fournier Gangrene Link Is 'Compelling'--What to Do?
https://www.medscape.com/viewarticle/912369

May 7th, 2019 - Welcome to Impact Factor, your weekly commentary on a breaking medical study. I'm Perry Wilson. A new class of medications, the SGLT2 inhibitors, has been killing it lately, with study after study in the New England Journal of Medicine documenting their benefits in patients with diabetes. Many of us feel that these drugs will become a central part of diabetes therapy in the near future. The twi...